1. All Products
  2. DINJIMCI - Imipenem / Cilastatin
  3. IMIPENEM 500mg/ CILASTATIN sodium 500mg, powder, vial
Public Pricelist

IMIPENEM 500mg/ CILASTATIN sodium 500mg, powder, vial

https://medicalguidelines.msf.org/en/node/1217
https://unicat.msf.org/cat/product/11708
STD DINJIMCI55V

Valid Article

Former Code(s): -X DINJZBD0135 DINJZBE0011 DINJIMCI5V- DINJZNL0103
The product is supplied (and stored) sterile, it must remain sterile until its use. Sterile = state of being free from all living microorganisms.
6.2.2 - Watch group antibiotics
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
6.2.5 - Antituberculosis medicines
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
J01DH51
Anatomical Therapeutic Chemical Classification according to WHOCC
PMF
The order of this product needs to be justified and is only acceptable under certain conditions.
1525
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

This combination does not exist.

See Related

Add article to list

   
Create Cancel

Add Kit To Wishlist

   
Create Cancel

IMIPENEM / CILASTATIN

Therapeutic Action

Antibacterial for systemic use, from carbapenem group

Broad spectrum antibiotic

Imipenem is always combined with cilastatin (no antibacterial activity) to inhibit a renal enzyme that inactivates imipenem.

Indications

Treatment of severe infections caused by Gram-positive and Gram-negative aerobic and anaerobic bacteria.

Drug-Resistant Tuberculosis (DR-TB) in adults and adolescents (from 15 years of age and > 30 kg).

Some restricted information has been hidden. Sign in to see this information

Instructions for use

Reconstitute the powder vial with 20 ml of 0.9% NaCl to obtain a reconstituted solution at 25 mg/ml imipenem.

The reconstituted solution must be given as deep IV infusion in 100 ml of 0.9% NaCl.

Administer clavulanic acid PO, 60 min prior each dose of imipenem/ cilastatin for prevention of carbapenem resistance.

Precautions for Use

Do not use in patients < 15 years and < 30 kg. Use meropenem in that case.

Do not mix with ringer lactate (incompatibility); can be administered via the Y-site.

May cause gastrointestinal disturbances, neurotoxicity and hypersensitivity reactions.

Storage

  • Below 25ºC - Protect from sunlight
  • After reconstitution, the solution remains stable for 4 hrs at room temperature or 24 hrs between 2ºC and 8ºC.
  • The reconstituted solution may turn colourless to pale yellow (no loss of activity). Discard if the solution turns brown.